CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor.

Saved in:
Bibliographic Details
Title: CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor.
Authors: Li J; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China.; Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China., Sun J; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Tan W; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Li G; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China., Xiao W; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China., Wu J; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China., Yang W; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China., Chen C; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Li Y; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Liu J; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Liu Y; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Liu D; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Chen XH; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China., Zhu R; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China., Huang R; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.; University of Chinese Academy of Sciences, Beijing 100049, China., Yan J; Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center; Laboratory Animal Center, Fudan University, Shanghai 200032, China.
Source: Theranostics [Theranostics] 2026 Jun 17; Vol. 16 (13), pp. 7495-7513. Date of Electronic Publication: 2026 Jun 17 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1838-7640
DOI:10.7150/thno.131907